+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07147101

Observing Different First-Line Immunotherapy Treatments in Adults with Advanced Liver Cancer and Their Effects on Immune Response

Led by Fudan University · Updated on 2026-04-21

150

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying advanced hepatocellular carcinoma HCC patients to evaluate how different first-line immunotherapy treatments affect the disease and the immune environment within tumors. This observational study compares combinations of immunotherapies, including anti-PD1 plus anti-VEGF, anti-PD1 plus tyrosine kinase inhibitors TKI, and anti-PD1 plus anti-CTLA4 therapies. The goal is to understand treatment response rates and changes in immune cells in the blood and tumor tissue. The treatments being studied include three main groups Sintilimab with a bevacizumab biosimilar given intravenously every three weeks, Camrelizumab with oral Rivoceranib daily plus intravenous Camrelizumab every two weeks, and a combination of Nivolumab and Ipilimumab administered intravenously on specific schedules. This non-interventional study observes patients receiving these treatments as part of their care without altering assigned therapies. Participants will be monitored for up to 42 months with evaluations including tumor scans to measure response, blood tests, and tissue samples to analyze immune profiles before and after treatment. Researchers will track objective response rates, disease control, duration and time to response, progression-free survival, overall survival, and any treatment-related side effects. The study aims to gather detailed information about how these immunotherapies work in advanced HCC and their effects on the immune system.

CONDITIONS

Brief Title

Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

Research Team

P

Peng Wang, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here